I would ask Dr. Miller these questions myself, but the ITF no longer responds to my e-mails. Therefore, I am posting my questions here in the hopes that a journalist (or a group of them) will pose some (or all) of them to Dr. Miller.
Asking and getting answers to these questions is critical to bringing transparency and accountability to the ITF's anti-doping programme. If you care about doping in tennis, you want these questions answered.
1. Why did ITF blood testing decrease by approximately 33 percent between 2006 and 2011?
2. In 2011, what proportion of out-of-competition missions resulted in no sample collected? What proportion of out-of-competition missions missions were conducted outside of the player's selected whereabouts hour?
3. For 2011 (and also in 2010), the WADA reported that the ITF recorded six adverse analytical findings and three anti-doping violations. What accounts for the difference between the two numbers?
4. How many EPO, HGH, and synthetic testosterone tests did the ITF conduct in 2010 and 2011? How many were conducted out-of-competition?
5. The tennis anti-doping programme (per Article 13.3) does not publicly identify players who are alleged to have committed an anti-doping rule violation unless and until a Tribunal has determined that a violation has been committed, and/or the violation has been admitted. However, the WADA Code (per Article 14.2.1) permits anti-doping organizations (ADOs) to publicly disclose this information prior to a Tribunal determination and/or the player admitting to a violation. Why has the ITF's anti-doping programme not implemented this public disclosure provision of the WADA Code?
6. How many tennis players are currently serving provisional suspensions?
7. Do players sometimes claim they are injured when they are, in fact, serving a provisional suspension? If so, does the ITF condone such actions?
8. Article 14.2.3 of the WADA Code states that in cases where it is determined, after a hearing or appeal, that an athlete did not commit an anti-doping rule violation, the decision may be disclosed publicly with the consent of the athlete. Further, the Code stats that the ADO shall use reasonable efforts to obtain such consent, and if consent is obtained, shall publicly disclose the decision in its entirety or in such redacted form as the athlete may approve. However, Article 8.8.5 of the ITF anti-doping rules states in cases where a Tribunal decides that an athlete did not commit an anti-doping rule violation (i.e., exonerated), then the decision shall not be published and its confidentiality shall be strictly maintained by all parties. Does the ITF believe Article 8.8.5 is compatible with Article 14.2.3 of the WADA Code? Does the ITF make any efforts to obtain consent from an athlete for public disclosure of exoneration decisions?
9. At this year's (2012) Wimbledon Wayne Odesnik suggested that the "substantial assistance" he provided to have his anti-doping ban halved was medical information substantiating his possession of HGH. This explanation is in conflict with the definition of "substantial assistance" in the tennis anti-doping programme (Article 10.5.3). Does the ITF agree with Wayne Odesnik's characterization of the assistance he gave? If not, please explain what assistance was offered and the state of any investigations initiated by that information. Has at least one other person (other than Odesnik) been pursued due to the information he provided? If so, has the investigation concluded? If so, what was the result? Were any doping violation(s), professional conduct violation(s), or criminal violation(s) uncovered?
10. At this year's Wimbledon, Andy Murray suggested that the ITF should not have reduced Mr. Odesnik's suspension, stating: "You want to make sure that people who are fined and suspended aren't let off because they are telling on other players. That is snitching." What is your view of Mr. Murray's statement?
11. What were the results the ITF's investigation into whether or not any players (or coaches or trainers) who worked with Dr. Luis Garcia del Moral did so for the purpose of doping? How was the investigation conducted (e.g., What was the methodology? Was an independent 3rd part retained to conduct the investigation?)
12. The French anti-doping authorities (AFLD) have been attempting to obtain permission from the ITF to conduct doping controls at ATP and WTA events in France. Previously, the ITF agreed to allow the AFLD to conduct doping controls at Roland Garros on a one-off basis in 2009. The AFLD has been seeking the ability to test at other events such as the Paris Masters, but the ITF will not agree to this. Why is this the case? Did the AFLD accept the original denial of the ability to test by the ITF, or did the AFLD appeal the issue to WADA, forcing WADA to consult with the ITF to understand why it wouldn't be appropriate for AFLD to do testing?
13. The ITF anti-doping unit has come in under-budget the last three years. Can you comment on why that occurred and what was done with the surplus funds?
14. In the ITF's submission on the WADA's current Code review process, you suggested that there may be a "cultural 'omerta'" in tennis. What led you to make such a comment?
15. Article 6.2 of the ITF's anti-doping programme states that "Where a Participant knows or suspects that any other Participant has committed an Anti-Doping Rule Violation, it shall be the Participant’s obligation to report such knowledge or suspicion to the ITF Anti-Doping Manager as soon as possible [...] Failure to comply with any of the foregoing without acceptable justification shall constitute an Anti-Doping Rule Violation within the meaning of Article 2.9."
- In September 2012, WTA player Vania King posted a comment on twitter indicating that the ITF needed tougher rules to curtail doping.
- In 2009, Mahesh Bhupathi stated that "A lot of players have been cheating."
- In 2010, Mardy Fish stated that he had "seen a few guys come and go who have cheated."
- In 2012, James Blake stated that "In tennis, I think, I'm sure there are guys who are doing it, getting away with it and getting ahead of the testers."
16. Please explain the rationale behind the ITF's use of loser-targeted testing at Grand Slam events between 2006 and 2009? Is the practice still used?
17. In 2011, the ITF granted a total of 64 Therapeutic Use Exemptions (TUE). How many different substances were approved for TUEs in 2011? What was the most common substance for which a TUE was granted? What was the most common condition for which a TUE was granted?
18. The ITF currently does not make use of the Athlete Biological Passport (ABP). Why is this the case? Does the ITF intend to adopt the ABP? If so, when? If not, why?
19. Article 14.4 of the WADA Code states that "Anti-Doping Organizations shall, at least annually, publish publicly a general statistical report of their Doping Control activities with a copy provided to WADA. Anti-Doping Organizations may also publish reports showing the name of each Athlete tested and the date of each Testing." Between 2006 and 2009, the ITF's annual statistical report showed the name of each player tested and the date of each testing. The ITF stopped reporting the date of each testing after 2009. Why did the ITF make this change?
20. What performance enhancing drugs do you think most benefit a tennis player? Why?